Details

Autor(en) / Beteiligte

• Rogatko-Koroś, Marta
• Mika-Witkowska, Renata
• Bogunia-Kubik, Katarzyna
• Wysoczańska, Barbara
• Jaskuła, Emilia
• Kościńska, Katarzyna
• Nestorowicz, Klaudia
• Dziopa, Joanna
• Szlendak, Urszula
• Gwozdowicz, Sławomir
• Graczyk-Pol, Elżbieta
• Lange, Andrzej
• Nowak, Jacek

Titel

Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results

Ist Teil von

• Archivum Immunologiae et Therapiae Experimentalis, 2016-12, Vol.64 (Suppl 1), p.63-71

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2016

Quelle

Springer LINK

Beschreibungen/Notizen

• Natural killer (NK) cell licensing status depends on clonal expression of inhibitory killer cell immunoglobulin-like receptors (iKIR) and short term HLA environment. Licensed NK cells are more efficient in tumor killing than unlicensed NK cells. Cognate KIR–HLA pairs in hematopoietic stem cell transplant (HSCT) donor and recipient are decisive for the possible change in the NK cell licensing status after HSCT. We assessed clinical outcomes in 297 patients with lymphoproliferative or myeloproliferative malignancies, or myelodysplastic syndrome in a model with upward licensing, downward resetting, and unchanged licensing genetics status after T cell replate HSCT from unrelated donors. We found extremely low (0%) relapse/progression incidence (RI), and better (59%) event-free survival (EFS) in recipients with upward licensing status and highly increased RI (37.5%), and reduced EFS (8%) among patients with the downward resetting status of repopulated donor NK cells after HSCT, as compared with unchanged NK cell licensing (RI 23%, EFS 47%). These trends were confirmed in adjusted multivariable models (for RI p  = 6.66E−09, OR = 1.47, 95% CI 1.29–1.66 and for EFS p  = 3.79E−13, OR = 1.67, 95% CI 1.50–1.84). Differences in the incidence of acute graft versus host disease (GvHD 62, 69, and 47%) and chronic GvHD (24, 44, and 15%, respectively) in three groups were insignificant. It would be rationale the preferential selection of the donors with upward licensing over downward resetting inhibitory KIR:HLA constellation and inclusion of the KIR genotyping in the donor selection algorithm for malignant patients. Further studies using enlarged cohorts of patients with more homogenous diagnosis are essential to reliably verify these preliminary data.